A study-by-study check
Semaglutide research: the claims beside the results
The studies tested different people and different goals. Putting each claim beside its test keeps the brochure language in check.
What are the clearest results?
The large studies measured changes that matter to patients. In the main weight study, average weight fell about 15% over 68 weeks [1]. In people with heart disease plus excess weight, major heart problems fell 20% [3]. In people with diabetes and kidney disease, major kidney events fell 24% [6].
Those three results came from three different groups. You can't swap one group for another. Which group fits you matters. This page starts with the kidney study, then covers heart health, weight, and blood sugar. It also looks at a rat study of hunger and a direct test against tirzepatide.
The numbers come from the named studies. They describe group averages, not your own outcome.
What did the Semaglutide kidney study find?
In 2024, a kidney study followed 3,533 adults. They had type 2 diabetes and ongoing kidney disease. A weekly 1.0 mg shot cut major kidney problems by 24% against placebo [6]. Its 95% figure tells how sure the researchers were, not how many people benefited. The full check favored the drug. The study counted kidney failure, kidney- or heart-linked death, and a lasting 50% fall in the kidneys' cleaning work. It tested what happened, not whether the copied GLP-1 gut hormone caused it.
A planned review then sorted people by their kidney illness at the start. The heart gain held across those groups [12]. The study didn't prove which body change caused that gain. Lower blood pressure, weight, and blood sugar may all have helped.
For the people studied, the kidney finding is solid. It isn't proof for every patient.
What did the heart studies find?
The SUSTAIN-6 study tested weekly shots in people with type 2 diabetes. They also had a high risk of heart trouble. The drug cut heart-linked death, stroke, and heart attack [2]. The first 95% figure describes how sure researchers were. Their full check favored fewer heart problems. Yet patients with old eye damage had more eye trouble. The eye study's 95% check was wide, so it can't say how often harm might happen.
A second study followed 17,604 adults without diabetes. Each carried excess weight and had heart disease. A 2.4 mg weekly shot cut major heart problems by 20% against placebo [3]. Its 95% certainty check favored the drug. The size of that gap didn't look like chance. The gain reached people without diabetes.
The third study tested a 2.4 mg shot in people with excess weight and heart failure. Heart failure doesn't always mean a weak squeeze. A stiff heart may squeeze with normal force but fill poorly. The shot eased symptoms, helped people move, and lowered weight [11]. Three groups gave three answers, not one promise.
What did studies find about Semaglutide weight loss?
STEP 1 enrolled adults without diabetes who had excess weight. They received a weekly 2.4 mg shot. At week 68, average body weight changed by -14.9%. Placebo brought a -2.4% change [1]. The gap was about 12.4 percentage points.
A two-year study found that much of the loss held while care went on [10]. Other work found better waist size, blood pressure, fats in blood, signs of swelling, and blood sugar [21]. Those extra checks were not the study's main goal. The mean can't tell you your result.
The drug made people eat less. It didn't raise the energy their bodies used.
How much did blood sugar change in type 2 diabetes?
Semaglutide was first approved to lower blood sugar. The injection and tablet each lowered the blood test covering about three months. Both also lowered body weight. Larger amounts tended to bring larger changes.
One direct trial compared Semaglutide with another weekly GLP-1 drug, meaning a medicine that copies the same gut-hormone message. The long-term blood sugar result and body weight fell more with Semaglutide than dulaglutide [7]. A review of daily-pill studies reported drops in blood sugar and weight [4]. It didn't find that the pill raised the major heart problems seen across GLP-1 drugs.
The studies support the blood-sugar and weight claims. Other trials tested the heart and kidney claims.
How did the drug change hunger in animals?
A rat study traced where Semaglutide went in the brain. It reached areas that help end a meal and control hunger. The rats ate less, chose different foods, and lost weight [22]. They did not burn less energy.
The study also found changes in brain cells tied to feeling full or hungry. One area can also play a part in nausea. That may help explain why less hunger and nausea can travel together.
This work was in rats, not people. It may explain the link. It doesn't show that people would respond the same way. For a plainer walk-through, see how does semaglutide work.
How do Semaglutide vs tirzepatide compare?
SURMOUNT-5 directly compared the drugs in 751 adults with obesity. At 72 weeks, average weight fell more with tirzepatide than with Semaglutide [23]. The size of the gap didn't look like chance.
An earlier test in people with diabetes pointed the same way. Tirzepatide lowered the blood sugar test covering three months and weight more than a weekly 1.0 mg Semaglutide shot [24]. GLP-1 is a gut hormone tied to blood sugar and hunger. Tirzepatide copies that message plus a second one. Semaglutide copies GLP-1 alone.
Tirzepatide won these weight tests. Semaglutide has the longer record for major heart and kidney problems.
Why is compounded Semaglutide treated differently?
The shortage stretched from about 2022 to early 2025. Federal rules let compounding pharmacies make Semaglutide during that gap. The opening became tighter once the shortage was over in 2025 [9].
The main trials used the approved, factory-made drug. They did not test every compounded version. Under the law, those products are also not the same. That difference can vanish in an ad, but it matters when you read the proof.
This is a plain account of the public record. It isn't legal advice, and this site supplies neither form.